AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10036609
Drug: 4.4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.4 mg/kg caffeine (C)
Trial: 10036609
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of behavioral reinforcement and caffeine (B + C)
Trial: 26882061
Drug: Topical dilute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dilute epinephrine (DE) 1% with lidocaine 1:100,000
Trial: 26882061
Drug: Topical phenylephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical phenylephrine 2.5%
Trial: 25534490
Drug: Alprostadil liposomal
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprostadil liposomal preparation
Trial: 31957889
Drug: Manual gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual gel testing
Trial: 26912491
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg DHA/d
Trial: 22251828
Drug: Neurocognitive habilitation
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein, A, recombinant, stabilized / respiratory syncytial virus pre-fusion F protein, B, recombinant, stabilized Injection [Abrysvo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurocognitive habilitation therapy (group therapy intervention for foster and adoptive caregivers and their children)
Trial: 15728081
Drug: IV saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV saline (group L)
Trial: 10541912
Drug: Whole-body vibration
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body vibration (WBV) with anticholinergic (scopolamine) and alpha-adrenergic blocking agents (prazosin)
Trial: 10541912
Drug: Whole-body vibration
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body vibration (WBV) with beta-adrenergic blocking agent (propranolol)
Trial: 9084534
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion at 3 mg/kg/h after 0.3 mg/kg bolus injection (Group A)
Trial: 9084534
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion at 4 mg/kg/h after 0.4 mg/kg bolus injection (Group B)
Trial: 9084534
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion at 5 mg/kg/h after 0.5 mg/kg bolus injection (Group C)
Trial: 6980404
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (4.5 g/day)
Trial: 8590162
Drug: H2-receptor blockers
RxNorm normalized name: H2-receptor antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2-receptor blockers (ranitidine or famotidine)
Trial: 7067923
Drug: Repeat action
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat action tablet containing 1 mg of azatadine maleate and 60 mg of d-pseudoephedrine sulfate
Trial: 7067923
Drug: Conventional tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional tablet of 60 mg of d-pseudoephedrine sulfate
Trial: 7067923
Drug: Conventional tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional tablet of 1 mg of azatadine maleate
Trial: 27228369
Drug: Ovulation induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovulation induction treatment
Trial: 26218723
Drug: Polypodium leucotomos
RxNorm normalized name: Polypodium leucotomos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypodium leucotomos (PLE) supplementation after photodynamic therapy (PDT)
Trial: 20376059
Drug: Heparin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (0.5 IU kg⁻¹ h⁻¹ in TPN solutions)
Trial: 20376059
Drug: No heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No heparin (TPN fluids without heparin)
Trial: 19034975
Drug: High-dose acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose acetaminophen and NSAIDs ingestion (group I)
Trial: 11142412
Drug: Topical DFMO
RxNorm normalized name: DFMO
DrugBank: Eflornithine (DB06243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical DFMO ointment (10% w/w) applied twice daily for 6 months
Trial: 11142412
Drug: Placebo hydrophilic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo hydrophilic ointment applied twice daily for 6 months
Trial: 8104062
Drug: Methylprednisolone acetate
RxNorm normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone acetate 60 mg (single im injection)
Trial: 8104062
Drug: Intranasal budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intranasal budesonide 200 micrograms bid (aerosol spray)
Trial: 8104062
Drug: Terfenadine 60
RxNorm normalized name: terfenadine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine 60 mg daily (tablets)
Trial: 3542441
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 (PGE2) 0.5 mg qid
Trial: 18249325
Drug: Aprotinin (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (loading dose of 2 x 10(6) KIU followed by continuous infusion at 5 x 10(5) KIU/h until skin closure)
Trial: 10781982
Drug: Imipenem/cilastatin (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilastatin (1.5 g daily)
Trial: 10781982
Drug: Meropenem (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem (3 g daily)
Trial: 2866715
Drug: 0.25% betaxolol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% betaxolol, treated twice daily for six weeks
Trial: 2866715
Drug: Placebo, treated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, treated twice daily for six weeks
Trial: 29137956
Drug: 19-Gy high-dose-rate
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 19-Gy high-dose-rate brachytherapy (HDR-BT)
Trial: 19889807
Drug: Legume-enriched, low-glycemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Legume-enriched, low-glycemic index diet (250 g/d, GI 38)
Trial: 12672185
Drug: Etanercept (Enbrel®)
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept (Enbrel®) administered subcutaneously twice weekly
Trial: 1516500
Drug: Morning NPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning NPH insulin (22 +/- 1 IU) plus 3.5 mg glibenclamide twice a day
Trial: 1516500
Drug: Bedtime NPH
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime NPH insulin (22 +/- 1 IU) plus 3.5 mg glibenclamide twice a day
Trial: 31306167
Drug: Combined hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined hormonal methods (DMPA-IM, norethisterone enanthate, implants)
Trial: 25475196
Drug: IV magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV magnesium sulfate 1 g just before the procedure
Trial: 23268365
Drug: 0.5% nitroglycerine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% nitroglycerine gel
Trial: 23268365
Drug: 1.25% nitroglycerine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25% nitroglycerine gel
Trial: 1467110
Drug: Interpleural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpleural morphine 2.5 mg i.p. and normal saline i.v. (group I)
Trial: 1467110
Drug: Morphine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 2.5 mg i.v. and i.p. saline (group II)
Trial: 6420025
Drug: Cimetidine 600
RxNorm normalized name: cimetidine 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 600 mg p.o.
Trial: 6420025
Drug: Morphine 10
RxNorm normalized name: morphine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 10 mg IM
Trial: 6420025
Drug: Morphine 10
RxNorm normalized name: morphine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 10 mg IM preceded by cimetidine 600 mg p.o.
Trial: 6420025
Drug: Cimetidine 600
RxNorm normalized name: cimetidine 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 600 mg p.o. and Morphine 10 mg IM
Trial: 28065188
Drug: Flavanone-rich orange
RxNorm normalized name: Orange
DrugBank: Orange (DB10549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavanone-rich orange juice (272.1 mg)
Trial: 28065188
Drug: Homogenised whole
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homogenised whole orange (452.8 mg)
Trial: 28065188
Drug: Orange juice
RxNorm normalized name: Orange juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orange juice (128.9 mg)
Trial: 28065188
Drug: Isoenergetic control
RxNorm normalized name: Octisalate 0.05 g in 1 mL / Avobenzone 0.03 g in 1 mL / Octinoxate 0.029 g in 1 mL / Octocrylene 0.022 g in 1 mL TOPICAL LOTION [For Men Maca Root Energetic Face Protector SPF 15]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoenergetic control (0 mg flavanones)
Trial: 25327311
Drug: Mitiglinide 10
RxNorm normalized name: mitiglinide
DrugBank: Mitiglinide (DB01252)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Mitiglinide 10 mg three times a day
Trial: 25327311
Drug: Sitagliptin 50
RxNorm normalized name: SITagliptin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 50 mg once a day
Trial: 19931080
Drug: DRP/20EE plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRP/20EE plus metformin (1,500 mg/d)
Trial: 19931080
Drug: DRP/20EE plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRP/20EE plus CPA (12.5 mg/d, 10 days per cycle)
Trial: 12401731
Drug: Irbesartan (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (150 mg b.i.d. orally)
Trial: 10216887
Drug: Docetaxel (Taxotere®)
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel (Taxotere®) as second-line chemotherapy
Trial: 7565904
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin K administration (group A)
Trial: 7565904
Drug: Intramuscular vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular vitamin K administration (group B)
Trial: 7565904
Drug: Intravenous vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vitamin K administration (group C)
Trial: 1980827
Drug: molindone at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: molindone at pre-established doses equivalent to pre-study neuroleptic
Trial: 1980827
Drug: haloperidol at
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: haloperidol at pre-established doses equivalent to pre-study neuroleptic
Trial: 1980827
Drug: molindone at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: molindone at 200% of pre-study dose
Trial: 1980827
Drug: haloperidol at
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: haloperidol at 200% of pre-study dose
Trial: 31532802
Drug: Therapist-guided internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-guided internet-based cognitive behavioral therapy (ICBT) for 14 weeks
Trial: 29273027
Drug: Citrus bergamia
RxNorm normalized name: CITRUS BERGAMIA LEAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrus bergamia extracts-based formulation (CitriCholess)
Trial: 26281160
Drug: Liquid probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid probiotic form based on Enterococcus faecium L3, daily dose of 1.5 x 10(9) CFU for three months
Trial: 19448381
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg twice a day with 20 mg esomeprazole once a day
Trial: 19448381
Drug: Ibuprofen in
RxNorm normalized name: ibuprofen Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen in ApoE epsilon4 carriers (n=27)
Trial: 11585018
Drug: Mifepristone (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (single dose) in early luteal phase
Trial: 11585018
Drug: Mifepristone (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (single dose) in mid-luteal phase
Trial: 11585018
Drug: Mifepristone alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone alone or in combination with a prostaglandin
Trial: 11585018
Drug: Mifepristone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (600 mg vs 10 mg)
Trial: 489921
Drug: Cimetidine 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 0.75 mg/kg bw
Trial: 489921
Drug: Cimetidine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 1.5 mg/kg bw
Trial: 489921
Drug: Cimetidine 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 3.0 mg/kg bw
Trial: 489921
Drug: Cimetidine 6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 6.0 mg/kg bw
Trial: 31306331
Drug: Testing or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testing or treatment for sexually transmitted infections
Trial: 28090798
Drug: GTR 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTR 20 mg/mL daily
Trial: 20945090
Drug: Sequential decision-making
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential decision-making process regarding adjuvant therapy options (one at a time)
Trial: 20945090
Drug: Sequential decision-making
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential decision-making process among higher-numeracy participants
Trial: 20945090
Drug: Sequential decision-making
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential decision-making process among lower-numeracy participants
Trial: 15323064
Drug: Olmesartan 40
RxNorm normalized name: HCTZ 25/OLMESARTAN 40MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan 40 mg/day
Trial: 19756164
Drug: Olmesartan 20
RxNorm normalized name: olmesartan 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan 20 mg/day plus HCTZ 12.5 mg/day
Trial: 19756164
Drug: Olmesartan 20
RxNorm normalized name: olmesartan 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan 20 mg/day (open-label)
Trial: 10826311
Drug: Endocrine agents
RxNorm normalized name: ENDOCRINE THERAPY ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine agents (antiestrogens, progestational drugs, aromatase inhibitors)
Trial: 6502506
Drug: Morphine sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulfate (10 mg) administered intravenously
Trial: 6502506
Drug: Cimetidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (300 mg po four times a day)
Trial: 3943267
Drug: Metoprolol (12.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (12.5, 25, 50, 100 mg)
Trial: 3943267
Drug: Bevantolol (18.75,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevantolol (18.75, 37.5, 75, 150 mg)
Trial: 3943267
Drug: Control observations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control observations (no drug)
Trial: 29762276
Drug: 40 IU
RxNorm normalized name: Oxytocin 40 IU/1 ML Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 IU injection of Botulinum toxin A (BoNT‐A)
Trial: 16343234
Drug: TEC (paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEC (paclitaxel 175 mg/m(2) followed by carboplatin AUC 5 with epirubicin 75 mg/m(2))
Trial: 16343234
Drug: TC (paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TC (paclitaxel 175 mg/m(2) followed by carboplatin AUC 5 without epirubicin)
Trial: 11195269
Drug: Serotonin reuptake
RxNorm normalized name: Selective serotonin reuptake inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonin reuptake inhibitors (SSRIs) with daily or intermittent dosing
Trial: 11195269
Drug: Luteal phase
RxNorm normalized name: Nuphar lutea leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteal phase only SSRI administration
Trial: 2064730
Drug: l-dopa (300-1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-dopa (300-1000 mg per day) with peripheral decarboxylase inhibitor (benserazide, carbidopa)
Trial: 6199470
Drug: Intravenous and
RxNorm normalized name: immune globulin intravenous and subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and intrathecal methotrexate without irradiation (IVIT group)
Trial: 15665012
Drug: Asoprisnil 10
RxNorm normalized name: Asoprisnil
DrugBank: Asoprisnil (DB06680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asoprisnil 10 mg QD or higher
Trial: 12164298
Drug: Dipstick assay
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dipstick assay for detection of Salmonella typhi-specific IgM antibodies
Trial: 10564562
Drug: Becaplermin gel-100
RxNorm normalized name: becaplermin Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Becaplermin gel-100 microg/g
Trial: 8728346
Drug: Doxazosin 1
RxNorm normalized name: doxazosin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 1 mg once daily for 10 days, followed by 2 mg once daily for 5 days (morning administration)
Trial: 8728346
Drug: Doxazosin 1
RxNorm normalized name: doxazosin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 1 mg once daily for 10 days, followed by 2 mg once daily for 5 days (evening administration)
Trial: 8728346
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of morning and evening administration of doxazosin
Trial: 1996576
Drug: Low-protein diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-protein diet (LPD, 0.6 mg/kg/d)
Trial: 1996576
Drug: Normal protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal protein diet (NPD, 1.3 mg/kg/d)
Trial: 30664303
Drug: Topiramate (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (300 mg/day, titrated over 6 weeks and maintained for 6 weeks)
Trial: 29298017
Drug: Local collagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local collagen treatment
Trial: 18317742
Drug: Glutamate injection
RxNorm normalized name: glutamate
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Glutamate injection (0.1 ml, 0.5 M) into latent MTrPs
Trial: 18317742
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline injection (0.1 ml, 0.9%) into latent MTrPs
Trial: 18317742
Drug: Glutamate injection
RxNorm normalized name: glutamate
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Glutamate injection into non-MTrPs
Trial: 18317742
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline injection into non-MTrPs
Trial: 18317742
Drug: Glutamate injection
RxNorm normalized name: glutamate
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Glutamate injection compared to isotonic saline
Trial: 10202876
Drug: Combined hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined hormone replacement therapy (oral E2, 1 mg daily for 12 months, then 2 mg daily) with 5 or 10 mg of dydrogesterone
Trial: 7607192
Drug: Naloxone (N;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (N; 1.2 mmol.l‐1; 3 ml)
Trial: 7607192
Drug: Placebo (P;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (P; 0.9% saline; 3 ml)
Trial: 393356
Drug: Indomethacin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (50 mg intravenous infusion over 30 minutes)
Trial: 393356
Drug: Indomethacin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (50 mg orally thrice daily for six days)
Trial: 31843374
Drug: Prescription requirement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription requirement for naloxone
Trial: 31843374
Drug: Average price
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average price of naloxone nasal spray
Trial: 11587994
Drug: Active smoke
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active smoke inhalation
Trial: 9403257
Drug: Povidone-iodine rinsing
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone-iodine rinsing 4 times daily
Trial: 7520905
Drug: Risperidone at
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone at doses of 6, 10, and 16 mg/day
Trial: 7520905
Drug: Haloperidol at
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol at a dose of 20 mg/day
Trial: 21848706
Drug: Roflumilast, 500
RxNorm normalized name: Roflumilast, 500 mcg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roflumilast, 500 µg once daily
Trial: 20141008
Drug: Emoxypin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emoxypin (150 mg)